Original Research
Published on 28 Oct 2022
Trigger related outcomes of takotsubo syndrome in a cancer population
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.1019284
- 2,006 views
- 1 citation
Type at least 3 characters
352 articles
Articles
Correction
Published on 27 Oct 2022
Corrigendum: Research on the mechanism and prevention of hypertension caused by apatinib through the RhoA/ROCK signaling pathway in a mouse model of gastric cancer
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.1070597
- 1,156 views
Original Research
Published on 19 Oct 2022
Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.901431
- 1,991 views
- 5 citations
Original Research
Published on 13 Oct 2022
Fatal heart disease in patients with bone and soft tissue sarcoma
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.951940
- 2,846 views
- 3 citations
Original Research
Published on 13 Oct 2022
Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.988013
- 3,667 views
- 12 citations
Review
Published on 11 Oct 2022
Heart failure and cancer: From active exposure to passive adaption
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.992011
- 2,112 views
- 1 citation
Original Research
Published on 06 Oct 2022
Effect of radiotherapy on cardiac-specific death in patients with non-malignant tumors of central nervous system and related clinical features
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.991621
- 1,304 views
- 1 citation
Case Report
Published on 06 Oct 2022
Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.955527
- 2,602 views
- 6 citations
Opinion
Published on 30 Sep 2022
Ten step academic-industry digital health collaboration methodology: A case-based guide for digital health research teams with the example of cardio-oncology
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.982059
- 3,307 views
- 3 citations
Case Report
Published on 30 Sep 2022
The surgical strategy of hormonally active primary cardiac paraganglioma sarcoma: A case report
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.941142
- 1,619 views
Case Report
Published on 29 Sep 2022
Overdrive pacing in the acute management of osimertinib-induced ventricular arrhythmias: A case report and literature review
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.934214
- 2,711 views
- 6 citations
Original Research
Published on 29 Sep 2022
Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm study
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.972455
- 3,204 views
- 5 citations
Opinion
Published on 29 Sep 2022
Leveraging innovation, education, and technology for prevention and health equity: Proceedings from the cardiology oncology innovation ThinkTank 2021
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.982021
- 2,256 views
Review
Published on 27 Sep 2022
Cardiac MRI assessment of anthracycline-induced cardiotoxicity
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.903719
- 5,244 views
- 8 citations
Original Research
Published on 23 Sep 2022
Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury?
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.922095
- 2,223 views
- 2 citations
Clinical Trial
Published on 23 Sep 2022
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab
in Cardio-Oncology
Frontiers in Cardiovascular Medicine
doi 10.3389/fcvm.2022.1000846
- 4,118 views
- 12 citations